Robin is the Professor of Mucosal Infection and Immunity, leading a team of 28 researchers within the Department of Medicine. The main focus of his research is the investigation of the mechanisms of mucosal HIV transmission and development of novel preventative strategies appropriate to a developing world setting. This has led to the establishment of international collaborations aimed at preclinical identification, development and selection of microbicide and vaccine candidates prior to formal clinical efficacy trials.
Robin has secured funding from the Wellcome Trust, NIH, European Commission, and the Bill and Melinda Gates Foundation. He currently holds a Grand Challenges for Global Health Initiative program grant to optimize vaginal vaccination against HIV infection co-funded by the Wellcome Trust and The Bill and Melinda Gates Foundation. Robin also leads the Mucosal Discovery Team for CHAVI-ID, the Center for HIV AIDS Vaccine Immunology and Immunogen Discovery funded by NIH. In addition, Robin provides scientific coordination for the European Microbicide program CHAARM (Combined Highly Active Anti-Retroviral Microbicides) and MOTIF (Microbicide Optimization Through Innovative Formulation for Vaginal and Rectal Delivery).
Robin chairs the WHO-UNAIDS HIV Vaccine Initiative Advisory Committee, the Research and Advisory Steering Committee of the International Partnership for Microbicides and is a member of the Scientific Advisory boards of the International Aids Vaccine Initiative (IAVI), Global HIV Vaccine Enterprise Scientific Committee (GHVE), the South African AIDS Vaccine Initiative SAAVI, the Scientific Advisory Board Review of the ANRS HIV Vaccine Research Program, and the Chinese Aids Vaccine Initiative (CAVI). Robin is on the editorial board of Mucosal Immunology and AIDS Research and Human Retroviruses and is an elected Fellow of the Society for Biology.
et al., 2016, HIV-1 CNS in vitro infectivity models based on clinical CSF samples, Journal of Antimicrobial Chemotherapy, Vol:71, ISSN:0305-7453, Pages:235-243
et al., 2016, TLR4 and TLR7/8 Adjuvant Combinations Generate Different Vaccine Antigen-Specific Immune Outcomes in Minipigs when Administered via the ID or IN Routes, Plos One, Vol:11, ISSN:1932-6203
et al., 2016, Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates, Journal of Virology, Vol:90, ISSN:0022-538X, Pages:5315-5328
et al., 2016, Short Communication: Limited Anti-HIV-1 Activity of Maraviroc in Mucosal Tissues, Aids Research and Human Retroviruses, Vol:32, ISSN:0889-2229, Pages:334-338
et al., 2016, Maraviroc and reverse transcriptase inhibitors combinations as potential preexposure prophylaxis candidates, Aids, Vol:30, ISSN:0269-9370, Pages:1015-1025